Cellworks Omics Biology Modeling (CBM) to predict therapy response and identifies novel biomarkers for carboplatin/cisplatin along with pemetrexed in NSCLC patients.

Cancer management using cytotoxic drugs is hampered by limited efficacy. Hence, a personalized treatment approach matching chemotherapy with appropriate patients remains a persistent and unmet need in the clinic. Genomic heterogeneity among patients creates an opportunity to discern key genomic aberrations and pathways that confer resistance and response to standard treatment options.

ASCO Meeting Library 2021 Non-Small Cell Lung Cancer